BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Bruin, D., Jansen, M., & Pereira, D. (2026). POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: A randomised, double-blind, placebo-controlled study. Frontiers in immunology, 16. Added by: Dr. Enrique Feoli (02/02/2026, 10:23) Last edited by: Dr. Enrique Feoli (02/02/2026, 10:29) |
 |
| Resource type: Journal Article DOI: 10.3389/fimmu.2025.1684307 BibTeX citation key: Bruin2026 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Inflammation resolution Creators: Bruin, Jansen, Pereira Collection: Frontiers in immunology |
Views: 10/29
|
| Abstract |
|
{Background and aim POLB 001 is an oral p38 mitogen-activated protein kinase (MAPK) inhibitor in development for the prevention of cancer immunotherapy-induced cytokine release syndrome (CRS). It has previously been shown to be well tolerated and capable of decreasing ex vivo lipopolysaccharide (LPS)-induced tumour necrosis factor (TNF) secretion in a phase 1 first-in-human trial. This study aimed to evaluate the anti-inflammatory effects of POLB 001 following in vivo LPS administration in healthy volunteers. Methods Participants received POLB 001 at doses of 30, 70, or 150 mg, or placebo, twice daily for seven consecutive days and were challenged locally with intradermal (ID) LPS on day 4 and systemically with intravenous (IV) LPS on day 6. Following ID LPS administration, skin perfusion and erythema were measured, and skin suction blisters were created to collect blister fluid containing infiltrating immune cells and extracellular fluid. Following IV LPS administration, circulating cytokine levels, leukocyte counts, leukocyte p38 MAPK phosphorylation levels, and vital signs were measured. Results
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli |